New study explores whether the withdrawal of prostacyclin therapies is possible after initiation of sotatercept, European Respiratory Journal 2025

Prostacyclin therapies, for pulmonary arterial hypertension, especially the parenteral ones, are associated with treatment burden, risks, and high costs. Authors Karen M Olsson, Jan Fuge, Da-Hee Park,Jan C. Kamp, and Marius M. Hoeper have investigated this possibility in a small series of pulmonary arterial hypertension patients treated with sotatercept. Withdrawal of selexipag was found safe, […]

New study explores whether the withdrawal of prostacyclin therapies is possible after initiation of sotatercept, European Respiratory Journal 2025 Read Post »

Tacrolimus versus cyclosporine immunosuppression in lung transplantation: a systematic review and meta-analysis, BMJ Open Respiratory Research, April 2025

A systematic review and meta-analysis to determine whether tacrolimus or cyclosporine is more effective at reducing chronic lung allograft dysfunction (CLAD) in lung transplant patients was publshed on the British Medical Journal in April 2025. The researchers analyzed 4 randomized trials involving 662 patients with a mean age of 45-55 years, mostly with Chronic Obstructive

Tacrolimus versus cyclosporine immunosuppression in lung transplantation: a systematic review and meta-analysis, BMJ Open Respiratory Research, April 2025 Read Post »

Societal Costs Associated With Pulmonary Arterial Hypertension Subgroups: A Study Utilizing Linked National Registries, Pulmonary Circulation, April 17, 2025

Pulmonary arterial hypertension (PAH) represents a significant economic burden on society, as revealed by a comprehensive Swedish study published on Pulmonary Circulation on April 17, 2025, examining the societal costs associated with this condition. The research tracked patients across various pulmonary arterial hypertension subgroups—idiopathic/hereditary pulmonary arterial hypertension, pulmonary arterial hypertension associated with connective tissue disease,

Societal Costs Associated With Pulmonary Arterial Hypertension Subgroups: A Study Utilizing Linked National Registries, Pulmonary Circulation, April 17, 2025 Read Post »

Physical Activity, Sleep, and Quality of Life in Pulmonary Arterial Hypertension: Novel Insights From Wearable Devices, Pulmonary Circulation, April 16, 2025

A study published in Pulmonary Circulation on April 16, 2025 investigated whether Fitbit wearable devices can provide meaningful clinical information about activity and sleep patterns in pulmonary arterial hypertension (PAH) patients. A total of 110 participants completed the 12-week baseline monitoring period. The cohort was median age 52.7 years (IQR: 40.9–60.5), female predominant (84% female),

Physical Activity, Sleep, and Quality of Life in Pulmonary Arterial Hypertension: Novel Insights From Wearable Devices, Pulmonary Circulation, April 16, 2025 Read Post »

“A wake-up call: key trends and policy asks for cardiovascular health in women”, European Parliament event, March 5, 2025

We were unfortunately unable to attend the European Parliament event which took place on March 5, 2025, but have read the minutes with great interest. Based on these we have put together some key takeaways as this topic is very relevant to pulmonary arterial hypertension patients, who are predominantly women. Opening Member of the European

“A wake-up call: key trends and policy asks for cardiovascular health in women”, European Parliament event, March 5, 2025 Read Post »

Balloon Pulmonary Angioplasty (BPA)’s development from its early applications to its current widespread adoption globally, Expert Review of Respiratory Medicine, April 14, 2025

Balloon Pulmonary Angioplasty (BPA) has revolutionized treatment for Chronic Thromboembolic Pulmonary Hypertension (CTEPH), as discussed in a comprehensive review published on April 14 2025 in the Expert Review of Respiratory Medicine. While Pulmonary Endarterectomy (PEA) continues to be the gold standard for patients with operable disease, many patients cannot undergo this surgical procedure due to

Balloon Pulmonary Angioplasty (BPA)’s development from its early applications to its current widespread adoption globally, Expert Review of Respiratory Medicine, April 14, 2025 Read Post »

Liberal fluid intake versus fluid restriction in chronic heart failure: a randomized clinical trial, Nature Medicine, March 30, 2025

A major study, led by the Radboud university medical center in the Netherlands, has shown that fluid restriction in people with stable heart failure offers no health benefits. On the contrary: it mainly causes thirst and discomfort. Whether patients drink less or not, there are no differences in overall health, hospital admissions, mortality, or medication

Liberal fluid intake versus fluid restriction in chronic heart failure: a randomized clinical trial, Nature Medicine, March 30, 2025 Read Post »

Pulmonary Artery Denervation (PADN) shows promise as a novel therapeutic approach in pulmonary hypertension, International Journal of Cardiology, May 2025 edition

Pulmonary Artery Denervation (PADN) shows promise as a novel therapeutic approach targeting the sympathetic nervous system’s role in pulmonary hypertension, reveal the findings of a metanalysis reviewing 14 studies, involving 372 patients. Pulmonary Artery Denervation improved several key hemodynamic parameters and clinical outcomes. The meta-analysis was published in the May 2025 edition of the International Journal

Pulmonary Artery Denervation (PADN) shows promise as a novel therapeutic approach in pulmonary hypertension, International Journal of Cardiology, May 2025 edition Read Post »

Medication adherence and clinical outcomes in patients with pulmonary arterial hypertension or distal chronic thromboembolic pulmonary hypertension, British Medical Journal Open Respiratory Research, April 5, 2025

The findings of a prospective study on 93 patients (66% women, 75% PAH, 25% CTEPH, 57±17 years), all on pulmonary hypertension-targeted oral medication, between 2013 and 2023, were recently published in the British Medical Journal Open Respiratory Research. These reveal that mean MPR (Medication Possession Ratio) and self-reported adherence were overall high, with 78% of patients

Medication adherence and clinical outcomes in patients with pulmonary arterial hypertension or distal chronic thromboembolic pulmonary hypertension, British Medical Journal Open Respiratory Research, April 5, 2025 Read Post »

Pulmonary arterial hypertension in Latin America. The age and comorbidity paradox, International Journal of Cardiology Congenital Heart Disease, March 2025

Pulmonary arterial hypertension (PAH), once seen mostly in young, healthy women, is now common among older adults with comorbidities in North America and Europe. In contrast, Latin American patients remain younger and healthier, with fewer related conditions. Possible Reasons Current Situation Latin American pulmonary arterial hypertension patients have: Future Concerns Rising obesity and aging populations

Pulmonary arterial hypertension in Latin America. The age and comorbidity paradox, International Journal of Cardiology Congenital Heart Disease, March 2025 Read Post »

Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death, New England Journal of Medicine, March 31, 2025

An article published in the New England Journal of Medicine on March 31 titled “Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death” reports on the findings of ZENITH, a phase 3 trial which evaluated sotatercept as an add-on therapy for high-risk pulmonary arterial hypertension patients (functional class II-IV) already on maximum

Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death, New England Journal of Medicine, March 31, 2025 Read Post »

Breaking news! Important update on the ZENITH trial on Winrevair (sotatercept) in pulmonary arterial hypertension from the American College of Cardiologists Scientific Annual Scientific Session, March 31, 2025

A very important update on the phase 3 ZENITH trial for Winrevair (sotatercept) in pulmonary arterial hypertension was presented today at the American College of Cardiologists Annual Scientific Session in Boston, USA. The ZENITH trial evaluated Winrevair compared to placebo in adults with PAH, WHO Group 1, functional class III or IV, at high risk

Breaking news! Important update on the ZENITH trial on Winrevair (sotatercept) in pulmonary arterial hypertension from the American College of Cardiologists Scientific Annual Scientific Session, March 31, 2025 Read Post »

Latest edition on “Mariposa” the quarterly magazine of the European PH organisation PHA Europe, is now out covering the annual conference, World PH Day and much more

In the Editor’s Note to “Mariposa” Hall Skaara, project manager at PHA Europe, highlights the organisation’s key 2024 achievements: Download the full issue of the magazine at this link on the PHA Europe website

Latest edition on “Mariposa” the quarterly magazine of the European PH organisation PHA Europe, is now out covering the annual conference, World PH Day and much more Read Post »

How tech improvements can benefit the chronic illness community, a testimony from Anna Jeter for Pulmonary Hypertension News, March 17, 2025

Anna Jeter, author of a recent article for Pulmonary Hypertension News, underwent a heart and lung transplant in 2018, and has since embraced smartwatch technology, and discovered valuable health management applications: Her smartwatch and phone helps track: Additional technology benefits include: Anna says she is thankful to live in a time of technological advancement that

How tech improvements can benefit the chronic illness community, a testimony from Anna Jeter for Pulmonary Hypertension News, March 17, 2025 Read Post »

The Association of Organ Procurement Organizations (AOPO) stresses how important language is organ donation and how it can save lives, March 27, 2025

Communication plays a crucial role in organ donation processes. According to the Association of Organ Procurement Organizations (AOPO), terminology choices can significantly impact public perception, potentially creating unnecessary fear that reduces donation rates. AOPO advocates for language that honors donors’ contributions and builds public confidence in the donation system. Recommended Terminology Shifts Surgical Procedure Terminology

The Association of Organ Procurement Organizations (AOPO) stresses how important language is organ donation and how it can save lives, March 27, 2025 Read Post »

Positioning Imatinib for Pulmonary Arterial Hypertension: A Dose Finding Phase 2 Study, American Journal for Respiratory Critical Care Medicine, March 2025

Imatinib for pulmonary arterial hypertension was the first antiproliferative approach in this condition’s treatment and may still be relevant today despite its complicated history. Originally developed as a cancer therapy (tyrosine kinase inhibitor), it showed very good results in pulmonary arterial hypertension, creating a lot of expectation when the IMPRES study was presented at the

Positioning Imatinib for Pulmonary Arterial Hypertension: A Dose Finding Phase 2 Study, American Journal for Respiratory Critical Care Medicine, March 2025 Read Post »

The US Food and Drug Administration (FDA) has accepted the new drug application resubmission for YUTREPIA™ (treprostinil) inhalation powder, March 28, 2025

Link: Liquidia Corporation announced on March 28, 2025, that the US Food and Drug Administration has accepted its resubmitted new drug application for YUTREPIA (treprostinil) inhalation powder. The treatment targets pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The FDA had previously granted tentative approval for both indications (see our

The US Food and Drug Administration (FDA) has accepted the new drug application resubmission for YUTREPIA™ (treprostinil) inhalation powder, March 28, 2025 Read Post »

Hoarseness as a rare symptom of idiopathic pulmonary arterial hypertension due to Ortner Syndrome, American Journal of Case Reports, March 28, 2025

The case study reported in a recent article for the American Journal of Case Reports, describes a 32-year-old male patient with idiopathic pulmonary arterial hypertension (IPAH) who presented with hoarseness. The hoarseness was attributed to Ortner syndrome, where an enlarged pulmonary artery compressed the left recurrent laryngeal nerve, causing left vocal fold paralysis. Diagnostic workup

Hoarseness as a rare symptom of idiopathic pulmonary arterial hypertension due to Ortner Syndrome, American Journal of Case Reports, March 28, 2025 Read Post »

Gabi Oniscu, Professor of Transplantation Surgery at the Karolinska Institutet, Sweden, and President of the European Society for Organ Transplantation (ESOT) speaking at TEDX Sweden, March 29, 2025

Gabi Oniscu, Professor of Transplantation Surgery at the Karolinska Institutet, Sweden, and President of the European Society for Organ Transplantation (ESOT), is schedule to give a TedX talk about ”The power of three: death, life and the gift in between”. He has written on his LinkedIn page that he will recount three stories “that capture

Gabi Oniscu, Professor of Transplantation Surgery at the Karolinska Institutet, Sweden, and President of the European Society for Organ Transplantation (ESOT) speaking at TEDX Sweden, March 29, 2025 Read Post »

The first edition of the year of the UK’s Pulmonary Hypertension’s EMPHASIS magazine is now out

EMPHASIS is the quarterly magazine of the UK Pulmonary Hypertension Association, PHA UK. You can read it at this link on the PHA UK website. This edition contains news of patient meetings, an update on sotatercept and an analysis of the future of research, a number of patient stories, an article on self identity and

The first edition of the year of the UK’s Pulmonary Hypertension’s EMPHASIS magazine is now out Read Post »

TRANSLATE »
Scroll to Top